BioAge Labs announced on Tuesday that its experimental drug, BGE-102, significantly reduced inflammation in a Phase 1 clinical study, positioning it as a potential treatment for cardiovascular risk prevention.
The study focused on individuals with obesity and elevated inflammation levels. Patients receiving a 60-milligram dose of BGE-102 experienced an 85% reduction in high-sensitivity C-reactive protein (hs-CRP) after one week. This reduction was maintained for up to three weeks. A similar effect was observed in participants who took a 120-milligram dose, as previously reported by the company.
Additionally, 87% of patients taking the 60-mg dose achieved hs-CRP levels below 2 mg/L—a threshold associated with a lower risk of cardiovascular complications.
Related articles
GLP-1 Drugs Linked to Better Breast Cancer Outcomes in Obesity and Diabetes Patients
A recent study shows that GLP-1 drugs may help improve survival rates in people with breast cancer, obesity, and diabetes. Image Credit: Tatsiana Volk...
Why Changing Pill Colors and Shapes at 73 Are More Than Just an Annoyance
At the ripe old age of 73, I take six drugs — four prescription and two over-the-counter pills — every day. I keep careful track of them. But recently...
PSA Screening Significantly Lowers Prostate Cancer Death Risk, Cochrane Review Confirms
Prostate-specific antigen (PSA) blood testing is likely to reduce the risk of death from prostate cancer, found a new review published on Thursday by...
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...
STAT Unveils 'The Deadliest Drug' Investigation: Alcohol-Related Deaths Surpass 178,000 Annually in the U.S.
Dear Readers, I want to bring your attention to “The Deadliest Drug,” a new STAT investigative series about our nation’s failure to address excessive...
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
Science-Backed: 8,500 Steps Daily for Sustainable Weight Loss
A new study demonstrates that 8,500 daily steps is the sweet spot for weight management. Stewart Cohen/Getty Images Walking 8,500 steps per day can he...